John SwartFounder

United States - Rochester, Minnesota

CEO at Cytotheryx, Inc. a preclinical cell therapy company focused on addressing acute, chronic and rare forms of liver disease through the use of primary human hepatocytes. Utilizing proprietary technology to produce clinical quantities of hepatocytes, Cytotheryx has a patented bioartificial liver to address acute liver failure, and allogeneic hepatocyte cell lines to treat chronic and rare forms of disease. Cytotheryx is excited to address this significant unmet need with its innovative programs.

Prior to joining Cytotheryx, I served as the President of Exemplar Genetics for 12 years, a small biomedical research company that developed innovative models of rare genetic diseases. Exemplar Genetics quickly established itself as the market leader in the field and was acquired in 2015.

Prior to co-founding Exemplar, I worked for twelve years for the global animal health business of Boehringer Ingelheim. While with Boehringer, I served in several capacities including leading a team in Research and Development that was focused on new product development and life cycle management, held the position of Executive Director of Operations for a site that produced animal health vaccines, served as Regulatory Affairs Liaison for USDA and FDA inspections, provided oversight for a GMP level Quality Assurance program, and worked with Sales and Marketing for Key Opinion Leader development. I also participated in Boehringer’s International Management Development Program leading a team that developed recommendations for improved business planning within the company.